Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on developing and commercializing genetic medicines using a proprietary redosable herpes simplex virus type 1 (HSV-1) vector platform. The company operates within the biotechnology and gene therapy industries, with a strategic emphasis on dermatology and rare genetic diseases. Its core value proposition is the localized, redosable delivery of gene therapies designed to address the underlying genetic causes of disease rather than symptoms.
The company’s primary revenue driver is its lead product, VYJUVEK, a topical gene therapy approved for dystrophic epidermolysis bullosa (DEB), a rare and severe genetic skin disorder. Krystal Biotech was founded in 2016 and progressed rapidly from platform development to commercialization, achieving U.S. Food and Drug Administration approval for VYJUVEK in 2023. Since its inception, the company has evolved from a research-focused startup into a vertically integrated gene therapy company with internal manufacturing, commercialization, and clinical development capabilities.
Business Operations
Krystal Biotech operates through a single integrated business model centered on its HSV-1 gene therapy platform, which supports discovery, clinical development, manufacturing, and commercialization. The company generates revenue primarily from the sale of VYJUVEK in the United States, with commercialization activities supported by specialty pharmacy distribution and direct engagement with treatment centers. Its operations include in-house vector design, plasmid production, and commercial-scale manufacturing at company-controlled facilities.
The company conducts research and development for additional dermatology and ophthalmology indications, leveraging the same vector technology. International operations include regulatory and clinical activities to support potential ex-U.S. approvals, particularly in Europe. Krystal Biotech does not rely heavily on third-party manufacturing, which it views as a strategic advantage, and it has no disclosed material joint ventures; however, it maintains clinical, regulatory, and logistics partnerships necessary for global trials and distribution.
Strategic Position & Investments
Krystal Biotech’s strategy centers on expanding the use of its HSV-1 platform across multiple rare diseases with high unmet medical need, particularly those amenable to localized gene delivery. Growth initiatives include label expansion of VYJUVEK, geographic expansion outside the United States, and advancement of pipeline candidates targeting ocular and additional dermatologic indications. The company has invested significantly in internal manufacturing infrastructure to support both current commercial demand and future pipeline assets.
The company’s pipeline includes investigational gene therapies for conditions such as Netherton syndrome and ocular diseases, representing an expansion into new therapeutic areas while maintaining platform consistency. Krystal Biotech has not pursued large-scale acquisitions as a core strategy, instead favoring internal development. Its investments are primarily directed toward clinical trials, regulatory submissions, and capacity expansion to support long-term commercialization.
Geographic Footprint
Krystal Biotech is headquartered in Pittsburgh, Pennsylvania, which serves as the center for its corporate, research, and manufacturing operations. The company’s primary commercial presence is currently in the United States, where VYJUVEK is approved and marketed. U.S. operations account for the majority of revenue and operational focus.
Internationally, the company has an expanding footprint through clinical trials and regulatory engagement in Europe and other select regions, with the goal of obtaining additional marketing authorizations. While it does not maintain a broad network of foreign subsidiaries, its international influence is growing through global clinical development programs and preparation for future commercial launches outside North America.
Leadership & Governance
Krystal Biotech was founded by Krishnan Suthanthiran, who has played a central role in shaping the company’s scientific and strategic direction. The leadership team emphasizes vertical integration, scientific rigor, and long-term platform scalability as core elements of its operating philosophy. Governance is overseen by a board of directors with experience in biotechnology, finance, and regulatory affairs.
Key executives include:
- Krishnan Suthanthiran – Founder, Chairman, and Chief Executive Officer
- Suma Krishnan – President, Research & Development
- Laurent Grillet – Chief Financial Officer
- Kathleen Smith – Chief Operating Officer
- Jonathan Jarow – Chief Medical Officer
The leadership team’s strategic vision focuses on building a sustainable genetic medicines company by combining proprietary technology, internal manufacturing control, and disciplined commercialization in rare disease markets.